Regend Therapeutics (China)

Recent papers from Regend Therapeutics (China)

1. Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based TherapyNew England Journal of Medicine · 2026
2. Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal CancersAdvanced Science · 2026
3. Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trialThe Oncologist · 2026
4. Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's DiseaseAdvanced Science · 2026
5. Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myelomaJournal of Translational Medicine · 2026
6. A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I studyBlood · 2026
7. Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistance中国科学通报：英文版 · 2026
8. Long-term follow-up of satricabtagene autoleucel (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: A subgroup analysis.Journal of Clinical Oncology · 2026
9. Safety and preliminary efficacy of a novel armored mesothelin-targeted CAR-T therapy in advanced solid tumors.Journal of Clinical Oncology · 2026
10. Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: Updated results from the phase Ib BEACON study.Journal of Clinical Oncology · 2026
11. Impact of Ori-TTV particles on in vivo CAR-T cell engineering for the treatment of hematologic malignancies.Journal of Clinical Oncology · 2026
12. Concentration of DNA at the Cell Surface Dictates Transfection Efficacy: A Hyperbranched Poly(β-Amino Ester) Mediated Strategy for Enhanced Lentivirus ProductionPolymers · 2026
13. Abstract CT064: Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumorsCancer Research · 2026
14. Abstract CT078: First-in-human phase I study of UCL70802, a LACO-Stim armored Anti-CD70 CART cell therapy, in patients with metastatic clear cell renal cell carcinoma (mccRCC)Cancer Research · 2026
15. Abstract CT027: Safety and preliminary efficacy of a novel LACO-Stim armored mesothelin-targeted CART therapy in advanced solid tumorsCancer Research · 2026
16. Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy EfficacyCancer Research · 2026
17. NeuroD1 gene therapy inhibits glioma growth and extends life span through in vivo reprogramming approachMolecular Therapy Oncology · 2026
18. Abstract 5978: SPR2015, a highly potent and selective KRAS G12D (on) inhibitor, exhibits favorable pharmacokinetic behavior and significant anti-tumor efficacy against colorectal cancer as monotherapy in preclinical modelsCancer Research · 2026
19. Abstract 1534: OriC613: A novel therapeutic strategy for gastric and pancreatic cancers utilizing dual-targeting CAR-T cells against MSLN and CLDN18.2 with a favorable safety profile and potent efficacyCancer Research · 2026
20. Abstract 4571: Discovery and characterization of RGT-490, a mutant selective PI3Kα inhibitorCancer Research · 2026